74 related articles for article (PubMed ID: 1298587)
1. [Assay of urine cysteine proteinase in diagnosing gynecological malignant tumors].
Peng ZL
Zhonghua Fu Chan Ke Za Zhi; 1992 Sep; 27(5):273-5, 316. PubMed ID: 1298587
[TBL] [Abstract][Full Text] [Related]
2. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
Xi MR; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
[TBL] [Abstract][Full Text] [Related]
3. Beta-core fragment (beta-core/UGF/UGP), a tumor marker: a 7-year report.
Cole LA; Tanaka A; Kim GS; Park SY; Koh MW; Schwartz PE; Chambers JT; Nam JH
Gynecol Oncol; 1996 Feb; 60(2):264-70. PubMed ID: 8631549
[TBL] [Abstract][Full Text] [Related]
4. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study.
Schutter EM; Mijatovic V; Kok A; Van Kamp GJ; Verstraeten R; Verheijen RH
Anticancer Res; 1999; 19(6C):5551-7. PubMed ID: 10697615
[TBL] [Abstract][Full Text] [Related]
5. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
6. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of serum VEGF in women with ovarian tumors.
Oehler MK; Caffier H
Anticancer Res; 1999; 19(4A):2519-22. PubMed ID: 10470186
[TBL] [Abstract][Full Text] [Related]
9. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
10. [Primary research on saliva and serum CA125 assays for detecting malignant ovarian tumors].
Chen DX; Li FQ
Zhonghua Fu Chan Ke Za Zhi; 1990 Mar; 25(2):84-5, 123-4. PubMed ID: 2364796
[TBL] [Abstract][Full Text] [Related]
11. [The value of urine cystein proteinase and serum CA125 measurement in monitoring the treatment of malignant ovarian tumor].
Gao G; Peng Z; He B
Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):291-4. PubMed ID: 9389065
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
13. p16 expression in the female genital tract and its value in diagnosis.
O'Neill CJ; McCluggage WG
Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy.
Padungsutt P; Thirapagawong C; Senapad S; Suphanit I
Anticancer Res; 2000; 20(2B):1291-5. PubMed ID: 10810437
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
16. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
17. [Constitutive characteristics and change trend of gynecological malignant tumors in 8009 hospitalized patients in Guangxi Zhuang Autonomous Region].
Huang W; Li L; Yu DQ; Huang YL; Liu Y; Chen XQ; Tang BJ; Xu H; Ma G; Dong LH; Li L; Qiu Y; Bai H; Nong WZ; Li L; Zeng DY; Jiang FY; Lan Y; Ye Y; Tang XZ; Wang DX; Li HZ; Pan YB; Mo AX; Wu XY; Lei ZY; Zhou GP; Liu C; Su QH
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):22-5. PubMed ID: 17331416
[TBL] [Abstract][Full Text] [Related]
18. [Regulation of ceruloplasmin activity in oncogynecological diseases].
Gusarova IuN; Stepanova EV; Landesman EO; Koroleva OV; Vavilova TP; Makarov OV; Kosetskiĭ VN
Vopr Med Khim; 2002; 48(4):388-93. PubMed ID: 12506616
[TBL] [Abstract][Full Text] [Related]
19. Early diagnosis and predictors of malignancy of adnexal masses.
Murta EF; Nomelini RS
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):14-9. PubMed ID: 16493254
[TBL] [Abstract][Full Text] [Related]
20. [Investigation of serum immunosuppresive acidic protein levels in gynecological tumor].
Zhang W; Wang P; Zhao Y
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):194-6. PubMed ID: 11601039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
